Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Mister Car Wash, Inc.’s (NASDAQ: MCW) board of directors and its controlling stockholder, LGP, for potential ...

Leading securities law firm Bleichmar Fonti & Auld LLP announces that it has filed a class action lawsuit against Ardent Health, Inc. (NYSE:ARDT) and certain of the Company’s senior executives for ...

Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Plug Power Inc. (NASDAQ:PLUG) and certain of the Company’s senior executives for ...

Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against CoreWeave, Inc. (NASDAQ:CRWV) and certain of the Company’s senior executives for ...

Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against NuScale Power Corporation (NYSE:SMR) and certain of the Company’s senior executives ...

Divestiture streamlines operations and advances the Company’s strategy to fully exit non-core activitiesLOS ANGELES--(BUSINESS WIRE)--$NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global ...

Evox Therapeutics Ltd (“Evox” or the “Company”), a biotechnology company developing innovative therapies for genetically driven neurodegenerative diseases using a next-generation gene editing modality ...

Transformative clinical pipeline transaction will add CL-273, a pan-EGFR inhibitor, and CL-741, a Phase 1-Ready c-MET inhibitor, to Kairos Pharma's clinical portfolio to target multi-billion dollar ...

Clinical and BMclinical have merged to offer an expanded global clinical trial supply service, enhancing sourcing, packaging, ...

PDUFA target action date of June 30, 2026 for veligrotug for thyroid eye disease (TED); U.S. commercial preparations on track to support anticipated launch -- Marketing Authorization Application (MAA) ...

Alterome Therapeutics, a clinical-stage biopharmaceutical company pioneering the development of next-generation, small molecule targeted therapies for the treatment of cancer, today announced that ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the exercise of 35,059,448 warrants, which were ...